Fasting Glucose Longevity-Medicine Target Ranges: What the Evidence Actually Shows

What Fasting Glucose Actually Measures

Fasting glucose is a snapshot of blood sugar concentration after at least 8 hours without caloric intake. The number reflects hepatic glucose output, insulin sensitivity, and the residual action of the previous evening's metabolic state. A single draw takes about 30 seconds and costs under ten dollars, yet it predicts cardiovascular events, all-cause mortality, and progression to type 2 diabetes decades in advance.

The Basic Biochemistry

After an overnight fast, blood glucose is maintained almost entirely by hepatic gluconeogenesis and glycogenolysis. Skeletal muscle and adipose tissue are largely quiescent. A high fasting number therefore points directly at impaired insulin signaling in the liver, not just postprandial carbohydrate excess. That is why fasting glucose and fasting insulin together (expressed as HOMA-IR) give a far sharper picture of metabolic health than either marker alone. The formula is straightforward: HOMA-IR = (fasting glucose in mmol/L × fasting insulin in μIU/mL) / 22.5, with values above 2.0 suggesting meaningful insulin resistance in most published reference ranges (Bonora et al., Diabetologia 2000).

Why the 8-Hour Rule Matters

Eating within 8 hours raises glucose and blunts the clinical meaning of the result. Even black coffee triggers a modest cortisol and glucagon response in some individuals. The ADA Standards of Care in Diabetes 2024 specify a minimum 8-hour fast for diagnostic fasting plasma glucose (FPG) and recommend the test be performed in the morning to avoid diurnal variation. Afternoon fasting draws can read 5 to 10 mg/dL lower than morning draws in the same individual, which matters when you are trying to track whether someone sits at 84 or 92 mg/dL.

Standard Reference Ranges vs. Longevity-Medicine Targets

The conventional cutoffs most labs use come from the American Diabetes Association and reflect the glucose concentrations at which retinopathy risk rises sharply. They were never designed to define cardiovascular or all-cause mortality optima.

ADA Diagnostic Thresholds (2024)

The ADA 2024 Standards of Care define four categories:

| Category | Fasting Plasma Glucose | |---|---| | Hypoglycemia concern | <70 mg/dL | | Normal | 70 to 99 mg/dL | | Prediabetes (IFG) | 100 to 125 mg/dL | | Diabetes | ≥126 mg/dL (confirmed) |

A value of 99 mg/dL is technically "normal" by this scheme. However, population data tell a different story about what optimal means for longevity.

Where the Longevity Literature Places the Optimum

The Whitehall II prospective cohort (N=10,308, followed over 10 years) found that non-diabetic participants with fasting glucose in the 95 to 99 mg/dL band had a meaningfully higher incidence of incident diabetes and adverse cardiovascular markers than those in the 70 to 85 mg/dL band (Tabák et al., Lancet 2012). The transition from normal to prediabetes is not a cliff edge; it is a slope that begins well below 100 mg/dL.

A large meta-analysis of 102 prospective studies (N=698,782 participants, 52,765 cardiovascular events) published in JAMA showed a log-linear relationship between fasting glucose and cardiovascular disease risk starting at approximately 85 mg/dL in people without diagnosed diabetes (Emerging Risk Factors Collaboration, JAMA 2010). Each 18 mg/dL (1 mmol/L) increment above that inflection point was associated with a 17% higher cardiovascular disease hazard ratio (P<0.0001) after adjustment for conventional risk factors.

The DECODE Study Group analyzed fasting and 2-hour post-load glucose in 29,108 European adults and found that all-cause mortality risk was lowest in men with fasting glucose between 73 and 90 mg/dL, rising continuously above that range (DECODE Study Group, Lancet 1999).

Based on this body of evidence, the practical longevity-medicine target sits at 72 to 85 mg/dL for fasting plasma glucose. The number 72 is the lower anchor because sustained fasting glucose below 70 mg/dL raises its own concerns about counter-regulatory response and hypoglycemia unawareness in some populations.

The Prediabetes Band: 100 to 125 mg/dL Is Not a Benign Waiting Room

Many clinicians treat an impaired fasting glucose (IFG) result as a "watch and wait" finding. The data do not support that approach.

Conversion Rate to Type 2 Diabetes

The Diabetes Prevention Program (DPP, N=3,234) enrolled adults with IFG and impaired glucose tolerance. Without intervention, roughly 11% converted to type 2 diabetes per year in the placebo arm. Intensive lifestyle intervention cut that rate by 58%, and metformin 850 mg twice daily cut it by 31% compared to placebo (Knowler et al., NEJM 2002). The 10-year DPP Outcomes Study follow-up confirmed that lifestyle effects were durable even after the intensive program ended (Diabetes Prevention Program Research Group, Lancet 2009).

Cardiovascular Risk Already Present in Prediabetes

A 2019 meta-analysis in The BMJ (14 prospective cohort studies, N=129,140) found that prediabetes defined by IFG criteria was associated with a 15% higher risk of all-cause mortality (HR 1.15, 95% CI 1.06 to 1.25), a 20% higher risk of cardiovascular disease (HR 1.20, 95% CI 1.11 to 1.30), and a 25% higher risk of coronary heart disease compared to normoglycemia (Huang et al., BMJ 2016). Organ damage does not wait for the 126 mg/dL threshold.

HbA1c as a Companion Marker

Fasting glucose alone can miss significant glycemic variability. The ADA recommends confirming prediabetes with both FPG and HbA1c (prediabetes range 5.7 to 6.4%). In longevity panels, an HbA1c target of 4.8 to 5.4% corresponds roughly to the 72 to 85 mg/dL fasting glucose window and is supported by the NHANES-derived mortality U-curve data that showed lowest all-cause mortality in that HbA1c band (Selvin et al., Ann Intern Med 2010).

Fasting Glucose as a GLP-1 and TRT Baseline Marker

Before initiating semaglutide (Ozempic / Wegovy), tirzepatide (Mounjaro / Zepbound), or testosterone replacement therapy (TRT), a baseline fasting glucose draw is standard practice at HealthRX. The reasons differ by therapy.

GLP-1 Receptor Agonist Baselines

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo (P<0.001) (Wilding et al., NEJM 2021). Fasting glucose fell by an average of 6.2 mg/dL in the semaglutide group from a mean baseline of approximately 98 mg/dL. Without a baseline draw, you cannot quantify the glycemic response or detect the rare patient whose glucose paradoxically rises due to dietary changes that accompany rapid weight loss.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a 20.9% mean weight reduction at 72 weeks (Jastreboff et al., NEJM 2022). Fasting glucose improvement was dose-dependent, with the 15 mg dose reducing FPG by roughly 8 mg/dL in non-diabetic participants. Baseline capture is required to interpret that trajectory.

Testosterone Replacement and Glucose Metabolism

Hypogonadism is independently associated with insulin resistance. A systematic review and meta-analysis of 19 randomized controlled trials found that testosterone therapy in hypogonadal men reduced fasting glucose by a mean of 1.87 mmol/L (approximately 33.7 mg/dL) in men with type 2 diabetes and improved HOMA-IR across non-diabetic cohorts as well (Corona et al., Eur J Endocrinol 2016). A fasting glucose baseline therefore serves as both a safety screen and an outcome tracker for TRT protocols.

How to Interpret Your Fasting Glucose Result

The Three-Zone Clinical Framework

Zone 1 (Optimal): 72 to 85 mg/dL. This range aligns with the lowest point on most mortality and cardiovascular-risk curves in large prospective cohorts. Maintain with consistent sleep (7 to 9 hours per night), resistance training at least twice per week, and a dietary pattern that limits refined carbohydrates. A 2022 meta-analysis of 36 randomized trials confirmed that resistance training reduces fasting glucose by a mean of 4.2 mg/dL (P<0.001) independent of aerobic exercise (Liao et al., BMC Sports Sci Med Rehabil 2022).

Zone 2 (Suboptimal): 86 to 99 mg/dL. Technically "normal" but carries measurable cardiovascular and metabolic risk. This band warrants: repeat fasting draw, fasting insulin and HOMA-IR, HbA1c, and a 2-hour oral glucose tolerance test (OGTT) if HOMA-IR exceeds 2.0. Lifestyle intervention is the primary tool. The Emerging Risk Factors Collaboration data suggest a 17% per-mmol/L increase in cardiovascular risk begins in this zone (JAMA 2010).

Zone 3 (Impaired): 100 to 125 mg/dL. IFG by ADA criteria. The DPP showed 58% diabetes risk reduction with lifestyle and 31% with metformin. At this level, a HealthRX clinician will typically order a full metabolic panel, continuous glucose monitor (CGM) trial, and discuss whether metformin 500 mg once daily (titrated to 850 mg twice daily as tolerated) is appropriate given the patient's full risk profile.

Single Test vs. Serial Testing

One fasting glucose draw can be misleading. Acute illness, poor sleep, intense exercise the prior day, or undisclosed eating within 8 hours all shift the result. The ADA 2024 guidelines require confirmation on a second day for a diabetes diagnosis. For longevity optimization, HealthRX draws fasting glucose every 6 months in patients with Zone 2 or Zone 3 readings and annually in confirmed Zone 1 patients. Trending matters more than any single snapshot.

Continuous Glucose Monitors and What They Add

A 14-day CGM trial (Abbott FreeStyle Libre 3 or Dexterity Dexcom G7) captures information no fasting draw can: postprandial spikes, nocturnal glucose excursions, and the area under the glucose curve across real dietary conditions.

CGM-Derived Metrics for Longevity Panels

The key CGM variables used alongside fasting glucose in longevity medicine panels are:

• Time in range (TIR): percentage of readings between 70 and 140 mg/dL. A 2019 consensus report endorsed by the ADA recommends TIR above 70% for most adults (Battelino et al., Diabetes Care 2019).
• Mean glucose: CGM mean below 100 mg/dL aligns with the longevity target window.
• Glucose management indicator (GMI): a CGM-derived HbA1c estimate. A GMI below 5.7% matches the optimal HbA1c band.
• Coefficient of variation (CV): CV below 36% indicates stable glucose. High variability, even with a normal mean, is associated with endothelial dysfunction in non-diabetic adults (Su et al., Cardiovasc Diabetol 2019).

Fasting Glucose vs. CGM Fasting Readings

CGM sensors read interstitial fluid glucose, which lags plasma glucose by 5 to 15 minutes and reads approximately 5 to 10 mg/dL lower during rapid glucose excursions. The morning fasting CGM value (taken after 30 minutes of wakefulness to let the dawn phenomenon stabilize) correlates well with lab FPG (r = 0.88 in the REPLACE-BG trial Aleppo et al., Diabetes Care 2017) but should not replace a venipuncture draw for formal diagnosis or baseline documentation.

Dietary and Lifestyle Factors That Move Fasting Glucose

What Raises It

The biggest drivers of a chronically elevated fasting glucose in non-diabetic adults are: visceral adiposity (HOMA-IR rises approximately 0.1 per 1 kg increase in visceral fat mass), short sleep duration (6 hours vs. 8 hours increases fasting glucose by a mean of 5 mg/dL in controlled crossover trials Spiegel et al., Sleep 1999), chronic psychological stress (cortisol drives hepatic gluconeogenesis), and high dietary refined-carbohydrate load. Alcohol consumed the night before a draw can paradoxically lower fasting glucose through hepatic alcohol metabolism competing with gluconeogenesis, generating a misleadingly low result.

What Lowers It

The evidence base is cleanest for four interventions:

1. Weight loss: Each 1 kg of body weight lost reduces fasting glucose by approximately 0.45 mg/dL in overweight non-diabetic adults, based on pooled data from the Look AHEAD trial (N=5,145) (Look AHEAD Research Group, NEJM 2013).
2. Resistance training: Mean reduction of 4.2 mg/dL in the Liao et al. 2022 meta-analysis (PubMed).
3. Dietary fiber: Each 10 g/day increase in soluble fiber reduces FPG by approximately 3.4 mg/dL based on a 35-trial meta-analysis (Zhu et al., Eur J Clin Nutr 2018).
4. Metformin: In the DPP, metformin 850 mg twice daily reduced FPG by 4.4 mg/dL from a mean IFG baseline, independent of weight change (Knowler et al., NEJM 2002).

The Full Glucose Panel: What HealthRX Orders Alongside FPG

A fasting glucose number without context is like a single frame from a film. The complete picture requires several companion tests ordered simultaneously.

Core Companion Tests

• Fasting insulin: Required to calculate HOMA-IR. Available at most reference labs; target fasting insulin is <8 μIU/mL for optimal insulin sensitivity (Bonora et al., Diabetologia 2000).
• HbA1c: Reflects 90-day average glucose. Longevity target: 4.8 to 5.4%. ADA prediabetes threshold: 5.7% (ADA 2024).
• 2-hour OGTT: The most sensitive single test for impaired glucose tolerance. The DECODE study showed 2-hour glucose was a stronger all-cause mortality predictor than fasting glucose alone (DECODE Study Group, Lancet 1999).
• Fasting triglycerides and HDL-C: An elevated triglyceride-to-HDL ratio (above 3.0 in mg/dL units) is a proxy for insulin resistance when a full HOMA-IR is not immediately available (Salazar et al., J Diabetes Res 2017).
• hsCRP: Chronic low-grade inflammation worsens insulin receptor signaling. The AHA/CDC joint statement classifies hsCRP above 3.0 mg/L as high cardiovascular risk, a cutpoint that frequently co-occurs with glucose in the 90 to 99 mg/dL suboptimal zone.

When to Add an OGTT

The ADA 2024 guidelines state: "The 2-h PG during a 75-g OGTT is the only test that can identify people with isolated impaired glucose tolerance." Isolated IGT (normal FPG, 2-hour glucose 140 to 199 mg/dL) is present in a substantial minority of individuals with normal fasting glucose but elevated cardiovascular risk. Any patient with fasting glucose above 90 mg/dL and a strong family history of type 2 diabetes or cardiovascular disease should have an OGTT ordered, not just repeat FPG.

Fasting Glucose Targets by Population Subgroup

The 72 to 85 mg/dL longevity target applies primarily to otherwise healthy adults aged 25 to 65 pursuing metabolic optimization. Several subgroups require modified targets.

Older Adults (Age 65 and Above)

The ADA 2024 Standards of Care specify less stringent targets for older adults with complex health status, recommending FPG targets that avoid hypoglycemia. Fasting glucose below 80 mg/dL in a 75-year-old on multiple medications carries hypoglycemia risk that outweighs the theoretical cardiovascular benefit of tight glycemic control. A practical floor of 80 mg/dL is reasonable for healthy older adults; 85 to 95 mg/dL is appropriate for those with comorbidities.

Women With PCOS

Polycystic ovary syndrome affects approximately 6 to 12% of reproductive-age women and carries a 2 to 4-fold elevated risk of type 2 diabetes (Moran et al., Hum Reprod Update 2010). The Endocrine Society 2018 Clinical Practice Guideline for PCOS recommends screening with FPG and 2-hour OGTT at diagnosis and every 1 to 3 years thereafter. In women with PCOS and a fasting glucose above 90 mg/dL, inositol supplementation and metformin have each shown FPG-lowering effects in small randomized trials (Unfer et al., Gynecol Endocrinol 2012).

Patients on Glucocorticoids or Antipsychotics

Both drug classes drive fasting hyperglycemia through distinct mechanisms. Glucocorticoids increase hepatic glucose output and reduce peripheral insulin sensitivity; second-generation antipsychotics (particularly olanzapine and clozapine) promote weight gain and worsen insulin resistance. The ADA 2024 guidelines recommend baseline and periodic FPG testing in all patients starting these agents. Steroid-induced hyperglycemia often produces normal fasting values with markedly elevated postprandial glucose, making a 2-hour OGTT or CGM more informative than FPG alone in this group.